Chondroitin Sulfate CS b-Bioactive Delays the Progression of Knee Osteoarthritis, Study Finds

beadbb9b-265e-4f43-972f-34f9381b5b8carticleimage.jpg

28 Jun 2017 --- Bioiberica’s Chondroitin sulfate CS b-Bioactive delays osteoarthritis progression and is as effective as the anti-inflammatory drug celecoxib at improving the disease’s symptoms. These are the main conclusions of a clinical essay presented by Professor Jean Pierre Pelletier at the Annual European Congress of Rheumatology, held in Madrid. Conducted by Bioiberica, the MOSAIC clinical essay (a 24-month study on structural changes in knee osteoarthritis assessed by MRI with Chondroitin sulfate) is a multicenter, randomized, double-blind, controlled and comparative study, carried out in five medical centers in Quebec (Canada). 

A total of 194 patients suffering from knee osteoarthritis with inflammation (synovitis) and moderate pain participated in the study to assess the effects of chondroitin sulfate (1.200 mg/day) and celecoxib (200 mg day) over the loss of cartilage volume in knee osteoarthritis after 24 months. 

The participants underwent three Quantitative Magnetic Resonance scans: one at the beginning of the study, the second one after one year and a third one at the end of the study. The results revealed that the progression of knee osteoarthritis is slower in patients who received chondroitin sulfate CS b-Bioactive. This group experienced a statistically significant lower loss of cartilage volume as soon as after the first year of treatment, in comparison with those patients who received the anti-inflammatory drug.

Patients treated with chondroitin sulfate had a decrease in synovitis which was associated with a statistically significant decrease in cartilage loss. In addition to that, a post hoc analysis of this clinical trial concludes that chondroitin sulfate also has a protective effect by reducing the long-term progression of knee OA structural changes caused by a decrease in the loss of subchondral bone curvature. 

“This data proves that chondroitin sulfate may delay the advance of osteoarthritis in the long term, and identifies a possible new mode of action of chondroitin sulfate,” Professor Pelletier said. 

The MOSAIC study also evaluated the effects of both products on the disease’s symptoms. Among others, the study evaluated their effects on pain, function, stiffness, joint swelling and effusion; concluding that both treatments were equally efficient across the entire study, reaching a clinically relevant symptom improvement of around 50 percent.

“The study confirms that both products are effective for the treatment of osteoarthritis symptoms, although only chondroitin sulfate has the additional advantage of exerting a joint protection effect,” Professor Pelletier concludes.

Related Articles

Nutrition & Health News

“Unhelpful”: EU regulatory framework fuels nutrition industry dissatisfaction 

16 Feb 2018 --- A survey reveals that one-third of all nutrition industry professionals believe that the current EU framework for achieving a health claim on new products is stunting innovation because it’s complicated, expensive, long-winded and has several “gray areas.” And “regulation frustration” is a strong feeling running through the industry with many more professionals now believing the current EU regulatory environment is “unhelpful” – a 25 percent hike compared with statistics from the beginning of 2017. Experts are attributing this sharp rise in dissatisfaction to the EU’s tough stance on health claims and the current regulatory deadlock on botanicals.

Nutrition & Health News

Indulgence has reached even America’s healthiest eaters: research

16 Feb 2018 --- New research reveals even the US’ healthiest eaters reach for indulgence foods based on their emotional states. Forty percent of US food-brand lovers who rated their daily diet as extremely healthy agreed with the statement, “When I’m feeling down, I eat something indulgent to make me feel better.” The study, conducted by full-service food branding agency, Foodmix Marketing Communications, breaks out a large group of brand lovers into smaller, differentiated and more actionable consumer segments.  

Nutrition & Health News

Research driving demand for OPO in China’s formula market: Advanced Lipids

16 Feb 2018 --- OPO is increasing in popularity in China’s infant formula market, and according to Advanced Lipids, this is down to the growing body of scientific research backing the benefits of this ingredient. Also known as SN-2 palmitate, OPO is a premium quality ingredient that mimics the fatty acid profile of human milk.

Nutrition & Health News

Vegan diet improves diabetes markers in overweight adults: study

16 Feb 2018 --- A plant-based diet improves beta-cell function and insulin sensitivity in overweight adults with no history of diabetes, according to a new study published in Nutrients by researchers from the Physicians Committee for Responsible Medicine. Measuring the function of beta cells, which store and release insulin, can help assess future type 2 diabetes risk.

Nutrition & Health News

Ultra-processed foods linked to heightened risk of cancer: major BMJ study

15 Feb 2018 --- Although processed foods have long been thought to be significantly less healthy than non-processed foods, an observational study published yesterday in BMJ has added some stark figures to the link between ultra-processed foods and the risk of cancer. The study concluded that a 10 percent increase in the proportion of ultra-processed foods in the diet is associated with increases of 12 percent in the risk of overall cancer and 11 percent in the risk of breast cancer.

More Articles
URL : http://www.nutritioninsight.com:80/news/chondroitin-sulfate-cs-b-bioactive-delays-the-progression-of-knee-osteoarthritis-study-finds.html